Insilico Medicine vs SigTuple

Insilico Medicine has a disclosed valuation of $1.2B, while SigTuple's valuation is not publicly available, making a direct size comparison difficult. Insilico Medicine employs 350 people.

Insilico Medicine has raised more in total funding at $403M, compared to SigTuple's $20M — a gap of $383M. Combined, the two companies have completed 3 known funding rounds.

Insilico Medicine holds the higher Awaira Score at 67/100, compared to SigTuple's 60/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 7-point gap that reflects meaningful differences in scale or traction.

Insilico Medicine was founded by Alex Zhavoronkov in 2014. SigTuple was founded by Rohit Kumar Pandey in 2015. Visit each company's profile on Awaira for a full founder biography.

Insilico Medicine: Insilico Medicine is an AI-driven drug discovery and development company founded in 2014 and headquartered in the USA. The company leverages artificial intelligence, machine learning, and generative models to accelerate the identification and optimization of drug candidates across multiple therapeutic areas. Its core platform integrates physics-based modeling with deep learning to predict molecular properties, identify disease targets, and design novel compounds with improved efficacy and reduced toxicity. The company operates across several segments: AI-powered target identification, lead optimization, and clinical trial optimization. Notable applications include oncology, aging-related diseases, and fibrosis. Insilico Medicine has demonstrated its technology through partnerships with pharmaceutical companies and biotech firms seeking to reduce drug development timelines and costs. The platform has been applied to various disease targets, with some candidates advancing through development stages. With $403 million in total funding and a valuation of $1.2 billion, Insilico Medicine represents a significant player in the AI healthcare sector. The company went public, reflecting investor confidence in its technology platform and business model. Its competitive position centers on the integration of generative AI models with molecular biology expertise. The company competes alongside other AI drug discovery platforms while differentiating through its aging research focus and established pharma partnerships. Insilico Medicine uniquely combines generative AI with longevity research, targeting age-related diseases while maintaining traditional pharma collaboration channels. SigTuple: SigTuple develops AI-powered automated pathology solutions that digitize and analyze microscopy slides for blood, urine, sputum, and semen samples, enabling high-throughput diagnostic testing without the constant presence of trained pathologists. The company's AI-Minth platform uses robotic sample preparation, high-resolution imaging, and deep learning analysis to deliver diagnostic-grade results.\n\nThe company raised approximately $20M in Series B funding and has deployed its automated microscopy systems at diagnostic labs, hospitals, and blood banks across India, processing millions of diagnostic samples. SigTuple has received regulatory approvals for its diagnostic AI products and has established partnerships with major diagnostic laboratory chains.\n\nIndia faces a severe shortage of qualified pathologists relative to population, creating an acute need for AI-assisted diagnostic automation. SigTuple's approach of combining hardware, robotics, and AI in an integrated system addresses the complete diagnostic workflow rather than just the software layer, creating higher deployment barriers but also higher switching costs and stronger network effects from accumulated diagnostic data.

Insilico Medicine was founded first in 2014, giving it 1 year of additional market experience. SigTuple was founded later in 2015. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Insilico Medicine has approximately 350 employees, while SigTuple has approximately 100-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Insilico Medicine and SigTuple are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.